Key result
Computational simulations demonstrated that the omecamtiv mecarbil binding site in human β-cardiac myosin undergoes significant changes in size, shape, and polarity during the recovery stroke.
Why the study?
Protein motions affect small-molecule druggability, and interest in therapeutic myosin modulators has grown following the discovery of omecamtiv mecarbil.
Computational modeling reveals significant dynamic changes in the omecamtiv mecarbil binding site of human β-cardiac myosin, providing insights for developing conformation-selective myosin modulators.
May guide myosin modulator design accounting for dynamics; leaves open clinical translation of these computational findings.
The druggability of small-molecule binding sites can be significantly affected by protein motions and conformational changes. Ligand binding, protein dynamics and protein function have been shown to be closely interconnected in myosins. The breakthrough discovery of omecamtiv mecarbil (OM) has led to an increased interest in small molecules that can target myosin and modulate its function for therapeutic purposes (myosin modulators). In this work, we use a combination of computational methods, including steered molecular dynamics, umbrella sampling and binding pocket tracking tools, to follow the evolution of the OM binding site during the recovery stroke transition of human β-cardiac myosin. We found that steering two internal coordinates of the motor domain can recapture the main features of the transition and in particular the rearrangements of the binding site, which shows significant changes in size, shape and composition. Possible intermediate conformations were also identified, in remarkable agreement with experimental findings. The differences in the binding site properties observed along the transition can be exploited for the future development of conformation-selective myosin modulators.
No takes yet. Share an insight, caveat, or question.
Akter et al. (2023) studied this question. Computational modeling of human β-cardiac myosin was evaluated on Binding pocket dynamics and free energy changes along the recovery stroke. Computational simulations demonstrated that the omecamtiv mecarbil binding site in human β-cardiac myosin undergoes significant changes in size, shape, and polarity during the recovery stroke.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: